Every S-1 that AIM IMMUNOTECH INC (AIMI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow AIMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMI filings page.
AIM ImmunoTech Inc. has filed an S-1 to register up to 31,287,933 shares of common stock for resale by existing holders of Class H and Class I warrants and related placement agent warrants. AIM will not receive proceeds from these stockholder sales, though full cash exercise of the warrants could bring in about $14.5 million for general corporate purposes and working capital.
The filing highlights substantial potential dilution, as common shares could rise from 24,328,623 to 55,616,556 if all registered warrants are exercised. AIM describes its focus on developing Ampligen for late-stage pancreatic cancer and other oncology and antiviral indications, while also warning about NYSE American listing risks, possible penny stock status, and significant stock price volatility.
ImmunoTech Inc. filed Amendment No. 3 to its Form S-1 registration statement as an exhibits-only update, amending Item 16(a) in Part II while leaving the remainder of the registration statement unchanged.
The amendment provides a detailed estimate of issuance and distribution expenses totaling $272,262, including an SEC registration fee of $4,971.60, a FINRA filing fee of $5,900.00, and legal, accounting, agent and miscellaneous fees. It also restates Delaware law-based indemnification provisions for directors and officers, summarizes prior unregistered securities issuances to executives and directors under Section 4(a)(2) and Rule 701, lists extensive material contracts and corporate documents as exhibits, and includes standard Securities Act undertakings and signature blocks.
ImmunoTech Inc. is launching a rights offering registering subscription rights to purchase up to 12,000 Units, each with one Series G Convertible Preferred share, plus securities convertible into up to 9,996,000 common shares and exercisable for up to 19,992,000 additional common shares.
Each Unit is offered at a $1,000 subscription price, with one non-transferable right per common share (including shares underlying participating options and warrants) held as of February 10, 2026, and an over-subscription privilege. The offer is best-efforts, with no minimum proceeds and an expected net raise of about $10.65 million if fully subscribed.
The company plans to use proceeds for general corporate purposes, clinical and manufacturing costs for prospective Phase 2/3 pancreatic cancer trials, and repayment of certain debt. The offering also supports efforts to regain NYSE American equity compliance while advancing Ampligen-based oncology, antiviral, ME/CFS and post-COVID programs.
ImmunoTech Inc. is conducting a rights offering of 12,000 Units at $1,000 per Unit, each Unit consisting of one share of Series G Convertible Preferred Stock and 1,492 warrants. The preferred shares are convertible into up to 8,952,000 shares of common stock, and the warrants are exercisable for up to 17,904,000 additional common shares at $1.34 per share for five years.
Existing common stockholders and holders of specified options and warrants as of 5:00 p.m. Eastern on February 4, 2026 receive one non-transferable subscription right per share, with a basic right to buy one Unit and an over-subscription privilege, subject to proration and a 19.99% ownership cap. The rights expire at 5:00 p.m. Eastern on February 23, 2026, and the offering is on a best-efforts basis with no minimum.
Assuming full subscription, ImmunoTech expects net proceeds of about $10.65 million, excluding any warrant exercises, and could receive an additional $23.99 million if all warrants are later exercised for cash. The company plans to use proceeds for general corporate purposes, including clinical and manufacturing costs for pancreatic cancer trials, and to repay certain existing debt, while highlighting significant dilution, liquidity and NYSE American listing risks.